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Abstract 
 
Background: Syncope is a sudden transient loss of consciousness and postural tone 
with spontaneous recovery; the most common form is vasovagal syncope (VVS). During 
VVS gravitational pooling excessively reduces central blood volume and cardiac output. 
In VVS, as in hemorrhage, impaired adrenergic vasoconstriction and venoconstriction 
result in hypotension. We hypothesized that impaired adrenergic responsiveness due to 
excess nitric oxide (NO) can be reversed by reducing NO. Methods and Results: We 
recorded cardio-pulmonary dynamics in supine syncope patients and healthy 
volunteers, (ages 15-27) challenged with a dose-response (DR) using the α1- agonist 
phenylephrine (PE), with and without the NO synthase inhibitor L-NMMA. Systolic and 
diastolic pressures among control and VVS were the same, although increased after L-
NMMA and Saline+PE (volume and pressor control for L-NMMA).  HR was significantly 
reduced by L-NMMA (P<0.05) for control and VVS compared to baseline but there was 
no significant difference in HR between L-NMMA and Saline+PE.  Cardiac output and 
splanchnic blood flow were reduced by L-NMMA for control and VVS (P<0.05) 
compared to baseline while total peripheral resistance (TPR) increased (P<0.05).  
Phenylephrine DR for splanchnic flow and resistance were blunted for VVS compared to 
control after Saline+PE, but enhanced after L-NMMA (P<0.001). Post-synaptic α1-
adrenergic vasoconstrictive impairment was greatest in the splanchnic vasculature, and 
splanchnic blood flow was unaffected by PE. Forearm and calf α1-adrenergic 
vasoconstriction were unimpaired in VVS and unaffected by L-NMMA.   Conclusions: 
Impaired post-synaptic α1-adrenergic vasoconstriction in young adults with VVS can be 
corrected by NO synthase inhibition, demonstrated with our use of L-NMMA. 
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Introduction 
Syncope (fainting) is defined by a sudden transient loss of consciousness and postural 
tone due to cerebral hypoperfusion with spontaneous recovery (1). The most common 
form of syncope in the young is simple postural faint, denoted “vasovagal syncope” 
(VVS) (2), and is associated with vasodilatation and vagal induced bradycardia causing 
hypotension and loss of postural tone. VVS is extremely common with lifetime incidence 
approaching 50% (3) and can be induced in most people at different thresholds of 
orthostatic stress (4).  
 
VVS due to upright positioning is initiated by subdiaphragmatic gravitational blood 
pooling primarily within the venous system, thereby excessively reducing central blood 
volume (5). In the absence of skeletal muscle pump activity, venous return and cardiac 
output (CO) decreases. In healthy subjects, baroreceptors detect a postural decrease in 
arterial and cardiopulmonary stretch, and maintain blood pressure (BP) by a 
compensatory increase in total peripheral resistance (TPR) which provokes passive 
elastic recoil of venous blood, and also by active splanchnic venoconstriction (6). 
Maintenance of BP is also aided by an increase in heart rate (HR), which increases 
venous return and cardiac output provided that stroke volume (SV) does not fall 
excessively. This is the normal reflex response to orthostasis (7).  
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Most adults with VVS exhibit excessive pooling in the splanchnic circulation and lower 
extremities that contributes to increased central hypovolemia, reduced CO and a 
sustained increase in TPR (8-10). In younger adults and children, however, TPR initially 
increases but then decreases while upright, producing a fall in BP with or without large 
changes in CO (11-13). This is followed by a rapid decrease in BP and HR with circulatory 
collapse. Impaired adrenergic vasoconstriction has been consistently demonstrated in 
VVS in the young involving abnormalities of the splanchnic regional vasculature (14;15). 
 
VVS likely evolved as a defense against excessive blood loss during hemorrhage (16;17). 
The time course of hemodynamic impairment during gradual hemorrhage mirror the 
stages of initial BP stability, with a slow fall in BP associated with tachycardia, and a 
rapid decrease in BP and HR with circulatory collapse. Studies of hemorrhage in 
animals showed adequate endogenous norepinephrine production but the post-synaptic 
α1-adrenergic response to norepinephrine and exogenous adrenergic vasoconstrictors 
was impaired. This impairment was reversed by nitric oxide synthase (NOS) inhibition 
(18-20). We therefore hypothesized that young adult patients with recurrent VVS may also 
have an impaired post-synaptic α1-adrenergic response that can be reversed by NOS 
inhibition. 
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Methods  
 
Subjects 
 
To test this hypothesis we recruited 10 subjects with a history of recurrent fainting (6 
female, 21.2 ± 1.2 years) and 12 healthy non-fainting control subjects (8 female,  23.0 ± 
1.1years), all between 15-27 years of age. There were no differences in the ages, 
weight and body mass index comparing both groups. Fainters were referred to our 
center for investigation after experiencing at least 3 episodes of fainting within the last 
12 months. Fainters gave a medical history and underwent a physical examination, 
electrocardiography, echocardiography, and prolonged monitoring as needed to exclude 
cardiac and other medical causes of their fainting. Control subjects were recruited from 
among age and BMI matched volunteers. Control subjects reported no clinical illness, 
no orthostatic intolerance, and had never fainted. 
 
The diagnosis of VVS was primarily based on the clinical history. Key diagnostic 
features encompassed predisposing situations, prodromal symptoms, physical signs, 
and postdrome recovery and symptoms (21).  In all patients, past fainting was induced 
after prolonged standing and in two patients it was also triggered by noxious stimuli. 
Prodromal features included pallor, lightheadedness, nausea with abdominal 
discomfort, diaphoresis, a feeling of warmth, visual scotomata or frank loss of vision. 
Following the faint, unconsciousness lasted less than 30 seconds in all when supine 
and most patients felt profoundly fatigued afterwards. Exclusion criteria for participation 
in this study included any infectious or systemic disease (including cardiovascular 
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disease), other forms of orthostatic intolerance, competitive athletic training, recent 
long-term bed rest, use of nicotine containing products or pregnancy within the last 
year. Prior medication for syncope, if any, was stopped for at least 2 weeks prior to 
participation in this study. No subjects were taking neurally active or vasoactive drugs. 
VVS and healthy control subjects previously underwent an upright tilt table test to 70o in 
which symptoms and signs of real-world syncope were confirmed in VVS patients, and 
to ensure absence of orthostatic intolerance in controls under test conditions.  
 
Because prolonged upright tilt may invoke a fainting response in young healthy 
subjects, we limited the head-up tilt (HUT) testing to 10 min. We (10;12) have previously 
demonstrated that this is a sufficient tilt time for the comparison of orthostatic changes 
between control and syncopal subjects. All subjects in the syncope group fainted during 
the 10-min HUT without any provocation, whereas no subjects in the control group 
fainted or experienced presyncopal symptoms. 
 
All subjects were required to refrain from caffeine and xanthine-containing products for 
at least 72 hours prior to testing. All subjects were instructed to fast for at least 4 hours 
prior to testing. This study was approved by the Institutional Review Board of New York 
Medical College. All subjects 18 or older signed an informed consent; those younger 
than 18 assented to participate and their parent or legal guardian signed an informed 
consent. 
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Protocol 
 
All patients and control volunteers were instrumented on two separate days. On the first 
day they received intravenous administration of the nitric oxide synthase inhibitor, NG-
Monomethyl-L-arginine, monoacetate salt (L-NMMA).  On another day they received an 
equivolumic intravenous infusion of normal saline as a volume control. An amount of 
phenylephrine (PE), individualized for each subject, was added to the saline in order to 
produce blood pressure and heart rate changes equivalent to the reflex changes caused 
by the infusion of the L-NMMA. This is referred to as Saline+PE.  
 
Instrumentation 
Subjects arrived at our climate-controlled center at 9:30 AM and were instructed about 
the tests and instrumentation. Subjects were then instrumented while supine. A left 
antecubital vein catheter was placed for infusion of L-NMMA or for saline + PE. Beat-to-
beat blood pressure was measured by Finometer photoplethysmograph (FMS, 
Amsterdam, The Netherlands) on the right forefinger or middle finger calibrated to the 
brachial artery. The Finometer uses the Modelflow algorithm to estimate beat-to-beat 
relative cardiac output (CO) by pulse-wave analysis. Before experiments began, 
ModelFlow CO was calibrated against an Innocor inert gas rebreathing CO (Innovision, 
Denmark). We then placed paired electrodes using anatomic landmarks to estimate 
thoracic, splanchnic, pelvic, and calf segmental blood volumes, blood flows and 
vascular resistance by impedance plethysmography (9). Forearm and calf blood flow 
was also measured by venous occlusion plethysmography every 5 min (22).  Respiratory 
plethysmography (Respitrace, NIMS Scientific, Miami Beach, FL) and capnography 
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(Smith Medical PM, Waukesha, WI) measured changes in respiration and end tidal 
carbon dioxide (ETCO2). An electrocardiograph measured HR from the beat-to-beat 
cardiac electrical interval. Signals were acquired at 200 samples/s, multiplexed, and A/D 
converted using custom software. These measurements are routine for our usual “tilt 
table” studies. Following instrumentation, subjects remained awake and supine for 30 
minutes to acclimate. Baseline data were acquired. Thereafter either L-NMMA or saline 
was given by infusion on different days.   
 
L-NMMA infusion 
VVS patients and control subjects received the non-isoform specific NOS inhibitor L-
NMMA delivered as a 500μg/kg/min intravenous loading dose for 15 min, followed by a 
50μg/kg/min maintenance infusion. L-NMMA is the only parenteral experimental NOS 
inhibitor available for human use (Bachem, Switzerland; FDA IND exemption #76,314, 
J. Stewart). In all subjects, a steady state for HR, BP, TPR, and CO was reached during 
the maintenance L-NMMA infusion within 40 minutes. Maintenance L-NMMA continued 
throughout all subsequent measurements.  
 
Saline + phenylephrine infusion (denoted Saline+PE) 
On another day, separated by at least two days to allow for the elimination of L-NMMA, 
VVS patients and control subjects received saline delivered to simulate the fluid volume 
and timing of a loading dose of L-NMMA. During this maintenance phase a low dose of 
phenylephrine was slowly titrated until HR and BP were similar to HR and BP in the 
same subject after loading L-NMMA. This dose of phenylephrine was maintained 
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throughout the experiment. The amount of phenylephrine required to compensate for 
HR and BP never exceeded 0.2μg/kg/min in any subject. 
 
Phenylephrine Dose-Response 
After either L-NMMA or Saline+PE were infused and HR and BP stabilized, new post-L-
NMMA (or post-Saline+PE) baseline hemodynamic data were acquired. A 
phenylephrine dose response (Phenyl DR) was then obtained in each subject (23) by 
infusing additional phenylephrine at  0.5, 1.0, 2.0, 3.0, and 4.0 µg/kg/min for 10 min. At 
each dose we measured ModelFlow CO, arm and leg blood flows by venous occlusion 
plethysmography, cuff BP and HR at minutes 8-10 at each concentration. At each 
phenylephrine dose, data were also obtained using all beat-to-beat measurement 
modalities (e.g. impedance, HR, etc). Stopping criteria for the use of phenylephrine 
included a HR<40 bpm, a BP>160/85, or the subject’s request to stop. Not all subjects 
were able to receive all doses of phenylephrine before reaching stopping criteria. 
However, all patients were able to receive 0.5, 1.0, and 2.0 µg/kg/min infusions of 
phenylephrine each for 10 minutes in succession, and these doses were therefore used 
for comparison. These data were depicted graphically and used for analysis. Statistics 
were computed by including post-loading data (L-NMMA or Saline+PE) and the 
responses to 0.5, 1.0 and 2.0 µg/kg/min. 
 
Data Analysis 
During experiments mean arterial pressure (MAP) was calculated as (systolic BP 
+2*diastolic BP)/3 and total peripheral resistance (TPR) was calculated as MAP/CO. 
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The primary outcome variables were BP, HR, CO, and TPR; secondary outcome 
variables were changes in splanchnic, forearm and calf blood flows and related regional 
resistances calculated as MAP/flow. Thoracic (central) blood flow was measured as the 
CO. Paired t-tests were used to compare the response to drug loading shown in Table 
1.  
 
The dose-response data were analyzed as two separate experiments (L-NMMA and 
Saline + PE), using a repeated measures analysis of variance (RM-ANOVA).  For each 
experiment, there was one between factor (group, i.e., patient vs. control) and one 
within factor (concentration).  Within patient, outcomes were measured at four 
concentrations: pre-challenge baseline (0), 0.5, 1, and 2 ug/kg/min of PE concentration 
(CONC), which constituted the repeated measures.  The study was conducted on two 
separate days, with the L-NMMA conducted on the first day and Saline + PE on the 
second (separated by at least two days).  This was done to insure that the loading dose 
of Saline + PE matched the patie t’s fluid volume and pressor response to L-NMMA.    
 
The primary relationship of interest for both experiments was the GROUP by CONC 
interaction, which describes how patients and controls differ in their response to the 
concentration challenge under each experimental setting.  For these analyses, we 
assumed a covariance structure of compound symmetry.  Reported p-values reflect the 
interaction term using the Greenhouse-Geisser correction.  Further, since we assumed 
that, if there were a response to the concentration challenge for either group, the 
response would increase or decrease monotonically.  Thus, our interest was in the 
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difference in slopes between the study groups, rather than the group difference at any 
particular concentration level.  As such, no post-hoc pairwise comparisons of groups at 
concentration specific concentration levels were conducted.  Values are presented as 
means ± SEM.  Statistical significance was set at p ≤ 0.05. NCSS 2007 (NCSS, LCC, 
and Kaysville) statistical software was used for statistical analyses. 
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Results 
 
Baseline and Post-Drug Data 
These data are tabulated in Table 1. There was no significant difference in systolic 
blood pressure or diastolic blood pressure among control and VVS groups, although 
these pressures tended to be increased after L-NMMA and Saline+PE. Mean arterial 
blood pressure (MAP) however was significantly increased (P<0.05).   HR was not 
different at baseline, but was significantly reduced by L-NMMA (P<0.05) for control and 
VVS compared to baseline. Nevertheless, there was no significant difference in HR 
between L-NMMA and Saline+PE.  Neither respiratory rate nor ETCO2 (not shown) 
were affected by either L-NMMA or Saline+PE in both control and VVS subjects. CO 
(thoracic blood flow) and splanchnic blood flow were reduced by L-NMMA for control 
and VVS (P<0.05) compared to baseline while TPR was increased (P<0.05) compared 
to baseline.  There was no significant difference between L-NMMA and Saline+PE CO 
or TPR for either group. There was no effect of drugs on forearm or calf blood flow for 
controls and VVS.  
 
MAP and HR responses to phenylephrine 
MAP (top panels), HR (middle panels) and SV during Phenyl DR are shown in Figure 1. 
MAP monotonically increased for all subjects. MAP increased more in control than in 
VVS patients (P<0.01) during phenylephrine infusion (right panels). Loading with L-
NMMA (left panels) increased the MAP Phenyl DR for both control and VVS and their 
respective response curves became similar. HR decreased following infusion of 
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phenylephrine, was similar for both groups, and was shifted significantly and similarly 
for both groups after L-NMMA (P<0.001). SV increased significantly in VVS during 
phenylephrine infusions (P<0.01) but remained unchanged in controls.  After L-NMMA, 
SV decreased in a similar manner for both control and VVS with higher concentrations 
of PE (P=0.56). Thus, Phenyl DR for MAP at each dose tested was decreased in VVS 
after Saline+PE loading but was similar to control after L-NMMA loading. HR r sponse 
was similar for both groups and decreased with L-NMMA. 
 
CO and TPR responses to phenylephrine. 
CO and TPR during Phenyl DR are shown in Figure 2. CO monotonically decreased 
with phenylephrine for control subjects (C-PE) (P<0.001), but was not different 
compared to VVS subjects (VVS-PE). The presence of L-NMMA resulted in a decrease 
of CO with phenylephrine that was similar for both control and VVS.  
 
The TPR with Phenyl DR was the mirror image of CO. After Saline+PE loading TPR 
increased significantly for control during phenyl DR (P<0.001), but was not different 
from Saline+PE for VVS during phenyl DR.  The Phenyl DR for TPR was similar for both 
groups in the pr sence of L-NMMA and was shifted significantly upwards for VVS 
compared to VVS without L-NMMA (P<0.001). Thus, Phenyl DR was blunted in VVS 
after Saline+PE but was similar to control after L-NMMA loading.  
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Splanchnic blood flow (Fsplanchnic) and splanchnic vascular resistance (Rsplanchnic) 
responses to phenylephrine 
Fsplanchnic and Rsplanchnic during Phenyl DR are shown in Figure 3. While there was almost 
no change in Fsplanchnic and Rsplanchnic to increasing doses of phenylephrine for VVS after 
Saline+PE, these values decreased significantly for Controls (P< 0.01). There was 
however a markedly enhanced response to phenylephrine after L-NMMA (P<0.001). 
Thus for VVS in the presence of L-NMMA, Fsplanchnic decreased to a great extent, while 
Rsplanchnic increased to a greater extent than control in response to increasing doses of 
phenylephrine. In controls Fsplanchnic and Rsplanchnic were unaffected by L-NMMA.  
However in VVS after L-NMMA, Fsplanchnic was excessively decreased and Rsplanchnic  was 
excessively increased. 
 
Forearm and calf vascular resistance responses to phenylephrine  
In contrast to the splanchnic vasculature, the increase in forearm and calf vascular 
resistance shown in Figure 4 increased similarly during the Phenyl DR for control and 
VVS subjects and the presence of L-NMMA did not significantly affect these 
relationships.  These findings are consistent with data presented in Table 2, which show 
that there were no significant differences in calf and forearm blood flows in control and 
VVS patients at each concentration of phenylephrine tested.  
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Discussion 
The results of this study in young adults indicate that there is impaired post-synaptic α1-
adrenergic vasoconstriction in VVS patients compared to healthy volunteers which 
results in reduced TPR and CO responsiveness to phenylephrine in our subjects with a 
history of VVS. Interestingly, this post-synaptic α1-adrenergic vasoconstrictive 
impairment can be corrected following nitric oxide synthase inhibition using L-NMMA.  
 
We show that post-synaptic α1-adrenergic vasoconstrictive impairment is greatest in the 
splanchnic vasculature, based on our demonstration that splanchnic blood flow in the 
absence of nitric oxide synthase inhibition by L-NMMA is relatively unaffected by 
phenylephrine. However, following L-NMMA, splanchnic flow decreased in a dose-
dependent manner in both control and VVS subjects following phenylephrine 
administration. In contrast, forearm and calf α1-adrenergic vasoconstriction are 
unimpaired in VVS patients and apparently unaffected by L-NMMA.  
 
In the present investigation we were only interested in whether phenylephrine had an 
effect on group differences; whether the response slopes differed as concentrations of 
phenylephrine were increased.  Thus we were not interested in differences at each 
concentration or in identifying the concentration at which the departure became 
significant as this was deemed to be relatively unimportant.   
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These observations are consistent with findings of nitric oxide potentiated splanchnic 
hyporeactivity (24), blunted chemoreflex (25), abnormal cerebral autoregulation(26), and 
impaired cardiovagal baroreflex(27) which occur during the later presyncopal phase of 
VVS.  
  
Evidence from the literature that nitric oxide blunts adrenergic neurotransmission 
Nitric oxide is a fundamental signaling molecule with pleiotropic effects and ubiquitous 
distribution. Three separate NOS isoforms are recognized: neuronal NOS (nNOS), 
inducible NOS (iNOS) and endothelial NOS (eNOS). nNOS and eNOS are constitutively 
expressed and depend on calcium-calmodulin (28).  
 
nNOS is found in the brain and in peripheral tissues such as skin, kidney, and 
splanchnic vasculature where neuronal NO acts to modulate adrenergic 
neurotransmission (29). nNOS has been localized to “nitrergic” nerves that proliferate 
within the gastrointestinal tract and distribute with the parasympathetic nervous system 
(29). While local eNOS exerts endothelial mediated vascular effects which could directly 
mediate vasodilation in VVS (30;31), NO released from nitrergic nerves can act at pre-
junctional and post-junctional sites to reduce sympathetic transduction (32). Effects are 
largest in the splanchnic vasculature (33) and in the kidney (34) where the density of 
nitrergic nerves is greatest, and are most potent during sympathetic activation. 
 
Our previous work demonstrated nNOS dependence of the local skin heating response 
(35) while co-release of NO from cholinergic nerves in part mediates active cutaneous 
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vasodilation (36). Heat-induced NO vasodilation informs on its ability to blunt adrenergic 
vasoconstriction (37). The sympatholytic effect of NO in man may be less potent in 
skeletal muscle (38) although combined prostaglandin and NO inhibition augments 
adrenergic vasoconstriction during contraction(39). Excessive NO may play a role in 
autonomic failure (40).  
 
Splanchnic hyperemia occurs in real or simulated microgravity (bedrest in man, hindlimb 
suspension in rats) where it is associated with orthostatic intolerance, adrenergic 
hyporeactivity  (41;42), and enhanced microvascular production of NO through increased 
transcription of NOS isoforms (43;44).  Increased NO has been reported in both postural 
tachycardia syndrome and VVS (45-47) but those results are controversial due to 
measurement methods and lack of subsetting (46).  
 
Nevertheless, nitrergic NO modulation of adrenergic vasoconstriction causes splanchnic 
hyperemia and our data indicate that our patients with vasovagal syncope overproduce 
nitric oxide within the splanchnic circulation by pathways as yet undefined, resulting in a 
post-synaptic defect in adrenergic vasoconstriction. If present during orthostasis, such a 
defect could lead to a blunted response to sympathetic stimulation and potentiate VVS 
in this cohort of subjects. 
 
The effects of NO on the adrenergic system are protean. In this paper we examined 
only post-synaptic effects, which could include decreased number of adrenergic 
receptors – unlikely given the fairly rapid normalizing effects of L-NMMA. Post-synaptic 
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effects could also include interference with adrenergic binding and in the transduction 
process making them likely candidates for NO-induced vasoconstrictive downregulation. 
These candidate mechanisms cannot be distinguished based on current data. In 
addition, other unmeasured NO effects such as reduction of central sympathetic 
activation and ganglionic transmission may be important, and are subjects for 
subsequent investigation.  
 
These results, obtained in young adults, ages 15-27 years, may be different than those 
obtained from older adults.  There is an increase in the reporting of VVS with age and in 
females, there is a first peak of syncopal incidents occurring at 15-24 years, with 
another peak occurring at age 40. The mechanisms of VVS at various ages are unclear, 
but this increased incidence has been attributed to the increased use of vasoactive and 
cardioactive medications, decreased vascular compliance, diminished cardiac function, 
physical deconditioning and poorer health with age.  Therefore our findings of impaired 
post-synaptic α1-adrenergic vasoconstriction in VVS, which can be corrected by NO 
synthase inhibition, may be a finding that is unique to young adults. 
 
Limitations 
The study may be underpowered with respect to measurements of forearm and calf 
vascular resistance. Because of this we were unable to demonstrate changes in 
resistance after loading L-NMMA, although these noisy data could reflect a trend 
towards increased limb resistances with L -NMMA. However, the results do show that 
limb resistance following saline+PE loading is not different for VVS compared to control 
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subjects. In addition, due to the small sample size, significant findings may be products 
of type I errors given that there are multiple outcomes in addition to multiple testing for 
each outcome. 
Since the incidence of syncope is dramatically higher in older vs. younger adults, the 
findings of this study are likely not applicable across all age groups. Sex differences and 
menstrual phase were not distinguished. There were insufficient subjects for this 
purpose. However, no obvious difference in sympathetic nerve activity or 
vasoconstrictive ability by sex or menstrual phase has been found, although differences 
in total blood volume reduce blood pressure in women (48;49).  
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 Table 1. Baseline and Post-Drug-Load Characteristics 
 
(Post-Load = following L-NMMA or Saline+PE) 
 
 
 Control-Baseline Control Post-Load VVS Baseline VVS Post-Load 
Systolic BP (mmHg)     
LNMMA 117±2 123±2 121±4 120±6
Saline+PE 115±2 120±2 118±2 122±3 
   
Diastolic BP (mmHg)     
LNMMA 62±2 69±2 63±4 68±3 
Saline+PE 65±2 70±2 63±4 65±3 
   
MAP (mmHg)     
LNMMA 79±1 87±2* 80±2 85±1* 
Saline+PE 82±2 87±2* 81±1 84±2* 
   
HR (bpm)     
LNMMA 62±2 57±1* 62±4 58±1*
Saline+PE 64±2 62±3 62±4 64±3 
   
CO (L/min)     
LNMMA 4.8±0.4 4.2±0.4* 4.9±0.4 4.2±0.4* 
Saline+PE 5.2±0.4 4.6±0.5 4.8±0.4 4.6±0.5 
   
TPR (mmHg/L/min)   
LNMMA 16.4±1.8 20.3±2.2* 16.4±1.0 18.4±1.1* 
Saline+PE 16.1±1.1 18.1±1.5 15.8±1.2 17.1±1.0 
   
Splanchnic BF (L/min)   
LNMMA 1.5±0.2 1.2±0.1* 1.3±0.1 1.0±0.1*
Saline+PE 1.2±0.2 1.2±0.2 1.2±0.1 1.2±0.1 
   
Forearm BF (ml%/min)   
LNMMA 1.87±0.32 1.65±0.33 1.81±0.19 1.61±0.14 
Saline+PE 2.05±0.33 2.10±0.27 2.22±0.25 2.18±0.12 
   
Calf BF (ml%/min)   
LNMMA 2.41±0.57 2.33±0.54 1.70±0.60 1.74±0.58 
Saline+PE 1.93±0.59 1.82±0.55 1.57±0.32 1.54±0.58 
 
*=p<0.05 compared to baseline 
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Table 2. Cardiovascular dynamics and calf and forearm blood flows in control and 
VVS patients at each concentration of phenylephrine tested. 
 
 
 Baseline Post-Drug 0.5 µg/kg/min PE 1.0 µg/kg/min PE 2.0 µg/kg/min PE
Systolic BP VVS (mmHg)   
LNMMA 121±4 119±6 140±7 161±6 174±7
Saline+PE 118±2 122±3 129±4 137±4 151±4
  
Systolic BP Control (mmHg)  
LNMMA 113±2 123±2 136±4 149±4 169±5
Saline+PE 115±2 120±2 128±3 143±4 160±5
  
Diastolic BP VVS (mmHg)  
LNMMA 63±4 68±3 80±4 87±4 92±5
Saline+PE 63±4 65±3 71±5 77±2 83±4
   
Diastolic BP  Control (mmHg)   
LNMMA 62±2 69±2 78±3 90±3 96±3
Saline+PE 65±2 70±2 75±1 81±2 89±3
   
HR VVS (beats/min)   
LNMMA 62±5 58±3 53±3 48±2 41±2
Saline+PE 62±4 61±3 60±4 54±4 46±3
   
HR Control (beats/min)   
LNMMA 62±5 57±3 49±3 44±2 41±2
Saline+PE 64±4 62±3 58±3 51±2 46±2
   
Forearm BF VVS (ml%/min)   
LNMMA 1.81±0.19 1.61±0.14 1.11±0.18 0.87±0.18 0.86±0.13
Saline+PE 2.22±0.25 2.18±0.12 2.01±0.36 1.45±0.34 1.14±0.18
   
Forearm BF Control (ml%/min)   
LNMMA 1.87±0.32 1.65±0.33 1.58±0.58 1.50±0.30 1.38±0.34
Saline+PE 2.05±0.33 2.10±0.27 1.83±0.32 1.70±0.36 1.26±0.38
   
Calf BF VVS (mL%/min)   
LNMMA 1.70±0.60 1.74±0.58 1.26±0.41 1.16±0.38 1.11±0.39
Saline+PE 1.57±0.32 1.54±0.26 1.68±0.48 1.80±0.54 1.44±0.39
   
Calf BF Control  (mL%/min)   
LNMMA 2.41±0.57 2.33±0.54 2.14±0.71 2.07±0.78 1.90±0.83
Saline+PE 1.93±0.59 1.82±0.55 1.68±0.41 1.32±0.38 0.89±0.26
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FIGURE LEGENDS 
Figure 1.  Mean Arterial Pressure (MAP), upper panels,  heart rate (HR),  middle panels, 
and stroke volume (SV) lower panels during phenylephrine dose response for control 
subjects (solid lines) and vasovagal syncope subjects (dashed lines). Saline and low 
dose phenylephrine were infused to simulate the fluid volume and maintained (right 
panels) to assure that HR and MAP were similar to HR and MAP in each subject after 
loading L-NMMA (left panels). This is depicted as Post Saline+PE a d is shown for 
control subjects who received saline and phenylephrine (C-PE), control subjects who 
received L-NMMA (C+LNMMA), patients with vasovagal syncop  subjects who received 
saline and phenylephrine (VVS-PE) and patients with VVS who received L-NMMA 
(VVS+LNMMA). Following that, increasing concentrations of phenylephrine were 
infused each for 10 minutes. P values represent the group by concentration interaction 
effect.  
 
Figure 2.  Cardiac Output (CO), upper panels, and Total Peripheral Resistance (TPR), 
lower panels, during phenylephrine dose response for control subjects (solid lines) and 
vasovagal syncope subjects (dashed lines). Saline and low dose phenylephrine were 
infused to simulate the fluid volume and maintained (right panels) to assure that HR and 
MAP were similar to HR and MAP in each subject after loading L-NMMA (left panels). 
This is depicted as Post Saline+PE and is shown for control subjects (C-PE), control 
subjects who received L-NMMA (C+LNMMA), patients with vasovagal syncope subjects 
who received saline and phenylephrine (VVS-PE) and patients with VVS who received 
L-NMMA (VVS+LNMMA). Following that, increasing concentrations of phenylephrine 
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were infused each for 10 minutes. P values represent the group by concentration 
interaction effect. 
 
Figure 3.  Splanchnic Blood Flow (Fsplanchnic), upper panels, and Splanchnic Resistance 
(Rsplanchnic) lower panels, during phenylephrine dose response for control subjects (solid 
lines) and vasovagal syncope subjects (dashed lines). Saline and low dose 
phenylephrine were infused to simulate the fluid volume and maintai ed (right panels) to 
assure that HR and MAP were similar to HR and MAP in each subject after loading L-
NMMA (left panels). This is depicted as Post Saline+PE and is shown for control 
subjects who received saline and phenylephrine (C-PE), control subjects who received 
L-NMMA (C+LNMMA), patients with vasovagal syncope subjects who received saline 
and phenylephrine (VVS-PE) and patients with VVS who received L-NMMA 
(VVS+LNMMA). Following that, increasing concentrations of phenylephrine were 
infused each for 10 minutes.  P values represent the group by concentration interaction 
effect. 
 
Figure 4. Forearm and calf v scular resistances shown in Figure 5, increase similarly 
during the phenyl D-R for control and VVS subjects  Forearm Resistance (Rforearm), 
upper panels, and Calf Resistance (Rcalf), lower panels, during phenylephrine dose 
response for control subjects (solid lines) and vasovagal syncope subjects (dashed 
lines). Saline and low dose phenylephrine were infused to simulate the fluid volume and 
maintained (right panels) to assure that HR and MAP were similar to HR and MAP in 
each subject after loading L-NMMA (left panels). This is depicted as Post Saline+PE 
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and is shown for control subjects who received saline and phenylephrine (C-PE), control 
subjects who received L-NMMA (C+LNMMA), patients with vasovagal syncope subjects 
who received saline and phenylephrine (VVS-PE) and patients with VVS who received 
L-NMMA (VVS+LNMMA). Following that, increasing concentrations of phenylephrine 
were infused each for 10 minutes.  P values represent the group by concentration 
interaction effect. 
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